Literature DB >> 15909253

Does linezolid cause lactic acidosis by inhibiting mitochondrial protein synthesis?

Lluis Palenzuela1, Noah M Hahn, Robert P Nelson, Janet N Arno, Carol Schobert, Robert Bethel, Lisa A Ostrowski, Manjuli R Sharma, Partha P Datta, Rajendra K Agrawal, Jennifer E Schwartz, Michio Hirano.   

Abstract

Linezolid, an oxazolidinone antibiotic, inhibits bacterial protein synthesis by binding to 23S ribosomal RNA (rRNA). We studied 3 patients who experienced lactic acidosis while receiving linezolid therapy. The toxicity may have been caused by linezolid binding to mitochondrial 16S rRNA. Genetic polymorphisms may have contributed to the toxicity in 2 patients.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15909253     DOI： 10.1086/430441

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  27 in total

Review 1.  Antimicrobial agents for treatment of serious infections caused by resistant Staphylococcus aureus and enterococci.

Authors:  G M Eliopoulos
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-12       Impact factor: 3.267

2.  A case of lactic acidosis induced by linezolid.

Authors:  Juan Carlos Q Velez; Michael G Janech
Journal:  Nat Rev Nephrol       Date:  2010-04       Impact factor: 28.314

3.  Allogeneic hematopoietic SCT as treatment option for patients with mitochondrial neurogastrointestinal encephalomyopathy (MNGIE): a consensus conference proposal for a standardized approach.

Authors:  J Halter; Wmm Schüpbach; A Gratwohl; M Hirano; C Casali; R Elhasid; K Fay; S Hammans; I Illa; L Kappeler; S Krähenbühl; T Lehmann; H Mandel; R Marti; H Mattle; K Orchard; D Savage; C M Sue; D Valcarcel
Journal:  Bone Marrow Transplant       Date:  2010-05-03       Impact factor: 5.483

4.  Reversible inhibition of mitochondrial protein synthesis during linezolid-related hyperlactatemia.

Authors:  Glòria Garrabou; Alejandro Soriano; Sònia López; Jordi P Guallar; Marta Giralt; Francesc Villarroya; Jose A Martínez; Jordi Casademont; Francesc Cardellach; Josep Mensa; Oscar Miró
Journal:  Antimicrob Agents Chemother       Date:  2006-12-28       Impact factor: 5.191

Review 5.  Pharmacologically-induced metabolic acidosis: a review.

Authors:  George Liamis; Haralampos J Milionis; Moses Elisaf
Journal:  Drug Saf       Date:  2010-05-01       Impact factor: 5.606

6.  Comparative analysis of lactic acidosis induced by linezolid and vancomycin therapy using cohort and case-control studies of incidence and associated risk factors.

Authors:  Nobuaki Mori; Yoshio Kamimura; Yuki Kimura; Shoko Hirose; Yasuko Aoki; Seiji Bito
Journal:  Eur J Clin Pharmacol       Date:  2017-12-08       Impact factor: 2.953

Review 7.  Current concepts in antimicrobial therapy against select gram-positive organisms: methicillin-resistant Staphylococcus aureus, penicillin-resistant pneumococci, and vancomycin-resistant enterococci.

Authors:  Ana Maria Rivera; Helen W Boucher
Journal:  Mayo Clin Proc       Date:  2011-12       Impact factor: 7.616

8.  Nonclinical and pharmacokinetic assessments to evaluate the potential of tedizolid and linezolid to affect mitochondrial function.

Authors:  Shawn Flanagan; Edward E McKee; Debaditya Das; Paul M Tulkens; Hiromi Hosako; Jill Fiedler-Kelly; Julie Passarell; Ann Radovsky; Philippe Prokocimer
Journal:  Antimicrob Agents Chemother       Date:  2014-10-20       Impact factor: 5.191

9.  Early onset probable linezolid-induced encephalopathy.

Authors:  Jeffery Fletcher; Laura E Aykroyd; Eric C Feucht; James M Curtis
Journal:  J Neurol       Date:  2009-11-05       Impact factor: 4.849

Review 10.  Community-associated meticillin-resistant Staphylococcus aureus infections: epidemiology, recognition and management.

Authors:  Mukesh Patel
Journal:  Drugs       Date:  2009       Impact factor: 9.546
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.